Jove
Visualize
联系我们

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

170
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
170
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

217
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
217
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

305
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
305
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

698
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
698
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pilot study of gene mutations associated with Lynch syndrome in Slovak patients with breast cancer.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2023
Same author

PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.

Physiological research·2023
Same author

Importance of the genetics in the diagnostics of hydatidiform mole.

Ceska gynekologie·2021
Same author

Murine experimental models for studying the pathogenesis of coxsackieviruses.

Acta virologica·2020
Same author

Schiff base Cu(II) complexes as inhibitors of proteasome in human cancer cells.

Bratislavske lekarske listy·2019
Same author

Various AKIP1 expression levels affect its subcellular localization but have no effect on NF-kappaB activation.

Physiological research·2019
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

化剂作为抗神经母细胞瘤剂

C W D'Acunto1, H Gbelcová, R Kaplánek

  • 1Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic; Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic. helena.gbelcova@fmed.uniba.sk.

Physiological research
|October 27, 2023
PubMed
概括

新的化物化合物HLZ显示出对神经母细胞瘤的潜在作用. 这些分子通过阻止细胞周期进展和激活特定细胞信号通路,有效地抑制MYCN非放大神经母细胞瘤细胞.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.2K

相关实验视频

Last Updated: Jul 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.2K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 神经母细胞瘤是一种显著的儿科癌症,具有攻击性的形式往往对化疗有抗性.
  • MYCN基因放大是神经母细胞瘤预后不佳的关键指标.
  • 神经母细胞瘤中合物化合物的抗癌潜力在很大程度上仍未被探索.

研究的目的:

  • 调查新型化剂化合物HLZ (1-hydrazino phthalazine) 对神经母细胞瘤细胞系的疗效.
  • 确定HLZ对神经母细胞瘤细胞增殖,细胞循环,细胞亡和ROS产生的影响.
  • 阐明HLZ在神经母细胞瘤细胞中的作用机制,重点关注MYCN放大状态.

主要方法:

  • 利用了三个神经母细胞瘤细胞系,具有不同的MYCN放大水平.
  • 通过WST-1和甲基蓝试验评估细胞增殖.
  • 通过流细胞计分析了细胞周期分布.
  • 通过特定的药理抑制剂和西方斑点分析来研究亡.
  • 使用度测定法测量ROS产量.

主要成果:

  • HLZ化合物仅在MYCN非增强的神经母细胞瘤细胞中表现出有效性.
  • 在敏感细胞系中,HLZ治疗导致细胞周期在G0/G1阶段停止.
  • 作用机制涉及到细胞信号通路的激活,包括蛋白激酶C.

结论:

  • 新型HLZ化剂对MYCN非增强神经母细胞瘤具有选择性抗癌活性.
  • 对于神经母细胞瘤患者的一个子集来说,HLZ代表了一个潜在的治疗策略.
  • 对HLZ的机制和治疗应用的进一步研究是有必要的.